Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda;Évaluation du rapport coût-efficacité du traitement antirétroviral combiné pour la prévention de la transmission du VIH de la mère à l'enfant en ouganda

Bulletin of the World Health Organization

Volumn 90, Issue 8, 2012, Pages 595-603

  Kuznik, Andreas ^a   Lamorde, Mohammed ^b   Hermans, Sabine ^c   Castelnuovo, Barbara ^b   Auerbach, Brandon ^d   Semeere, Aggrey ^b   Sempa, Joseph ^b   Ssennono, Mark ^b   Ssewankambo, Fred ^b   Manabe, Yukari C ^b  

^a PFIZER INC   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

COST; DISEASE TREATMENT; DRUG; ECONOMIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; PREGNANCY; VERTICAL TRANSMISSION;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MOTHER CHILD TRANSMISSION; PREGNANT WOMAN; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; UGANDA;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UGANDA; ZIDOVUDINE;

UGANDA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84864520310     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.11.095430     Document Type: Article

References (36)

1. The world fact book. Africa: Uganda. Langley: Central Intelligence Agency;. 2011. Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/ug.html [accessed 21 May 2012].
2. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: United Nations Joint Programme on HIV/AIDS; 2010. Available from: http://www.unaids.org/globalreport/global_report.htm [accessed 21 May 2012].
3. PMTCT strategic vision 2010-2015: preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals. Geneva: World Health Organization; 2010. Available from: www.who.int/hiv/pub/mtct/strategic_vision.pdf [accessed 21 May 2012].
4. UNGASS country progress report Uganda: January 2008-December 2009. Kampala: Government of Uganda; 2010.
5. United Nations Special Session on HIV/AIDS. Implementing the declaration of commitment on HIV/AIDS: action guide for the United Nations country teams. New York: United Nations General Assembly; 2001.
6. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2010.
7. The integrated national guidelines on antiretroviral therapy, prevention of mother to child transmission of HIV and infant & young child feeding. Kampala: STD/AIDS Control Programme, Ministry of Health; 2011.
8. Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, Lamorde M et al. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS ONE 2011;6:e18193. doi:10.1371/journal.pone.0018193 PMID:21464895
9. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010;362:2282-2294. doi:10.1056/NEJMoa0907736 PMID:20554983
10. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008;359:130-141. doi:10.1056/NEJMoa073788 PMID:18525036
11. Shah M, Johns B, Abimiku A, Walker DG. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 2011;25:1093-1102. doi:10.1097/QAD.0b013e32834670b9 PMID:21505317
12. Generic antiretroviral drug pricelist. Kampala: Medical Access Uganda; 2011.
13. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2010 version). Geneva: World Health Organization; 2010.
14. Uganda Demographic and Health Survey. Calverton: ORC Macro; 2006.
15. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-1174. doi:10.1001/jama.283.9.1167 PMID:10703779
16. Taha TE. Mother-to-child transmission of HIV-1 in sub-Saharan Africa: past, present and future challenges. Life Sci 2011;88:917-921. doi:10.1016/j.lfs.2010.09.031 PMID:20933522
17. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178-1186. doi:10.1016/S0140-6736(02)08214-4 PMID:11955535
18. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009;49:1936-1945. doi:10.1086/648446 PMID:19916796
19. Hladik W, Stover J, Esiru G, Harper M, Tappero J. The contribution of family planning towards the prevention of vertical HIV transmission in Uganda. PLoS ONE 2009;4:e7691. doi:10.1371/journal.pone.0007691 PMID:19888347
20. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:1236-1243. doi:10.1016/S0140-6736(04)17140-7 PMID:15464184
21. Johansson KA, Robberstad B, Norheim OF. Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther 2010;7:3. doi:10.1186/1742-6405-7-3 PMID:20180966
22. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. HIV/AIDS and fertility in sub-Saharan Africa: a review of the research literature. New York: United Nations; 2002.
23. Murray C, Lopez A, editors. The global burden of disease. Cambridge: Harvard University Press; 1996.
24. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
25. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-573. PMID:17438315
26. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802. PMID:10485720
27. The World Bank Data Development Group. World development indicators. Washington: The World Bank; 2011.
28. World Health Organization [Internet]. Cost-effectiveness thresholds. Geneva: World Health Organization; 2011. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html [accessed 21 May 2012].
29. Orlando S, Marazzi M, Mancinelli S, Liotta G, Ceffa S, Giglio P et al. Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr 2010;55:631-634. doi:10.1097/QAI.0b013e3181f9f9f5 PMID:21934555
30. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR et al.; Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004;189:2154-2166. doi:10.1086/420834 PMID:15181561
31. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization; 2010.
32. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010;376:33-40. doi:10.1016/S0140-6736(10)60894-X PMID:20557927
33. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008;22:2291-2302. doi:10.1097/QAD.0b013e3283121ca9 PMID:18981768
34. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505. doi:10.1056/NEJMoa1105243 PMID:21767103
35. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929. doi:10.1056/NEJM200003303421303 PMID:10738050
36. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375:2092-2098. doi:10.1016/S0140-6736(10)60705-2 PMID:20537376